SAP AG is a global leader in enterprise resource planning (ERP) software and solutions that help organizations manage their business operations efficiently. The company provides a suite of applications designed to streamline processes across various functions, including finance, supply chain, human resources, and customer relationship management. SAP's innovative technologies, such as cloud computing and data analytics, empower businesses to harness data insights and improve decision-making. By serving a diverse range of industries, SAP enables companies of all sizes to enhance their productivity, drive digital transformation, and achieve sustainable growth. Read More
AT&T’s Q2 revenue increased 3.5% year-over-year to $30.8 billion, beating the analysts' consensus estimate of $30.4 billion, according to Fiscal AI data.
SAP on Tuesday reported second quarter profit and revenue that edged by Wall Street estimates. SAP stock dipped amid the size of the beat. For the quarter ending June 30,... Read More
Uniform and facility services provider Cintas (NASDAQ:CTAS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 8% year on year to $2.67 billion. On the other hand, the company’s full-year revenue guidance of $11.08 million at the midpoint came in 99.9% below analysts’ estimates. Its GAAP profit of $1.09 per share was 2.3% above analysts’ consensus estimates.
MicroStrategy’s journey from a business intelligence innovator to one of the world’s most prominent Bitcoin holders is a saga of risk-taking, reinvention, and relentless ambition. Over three decades, the company has gone from being a respected—if relatively niche—provider of enterprise software, to a household name among
Supermicro is shipping high-performance 4-socket servers for demanding enterprise applications. They offer advanced 6 Processors with P-Cores, up to 16TB of memory, and support for 6 GPUs, making them ideal for ERP, AI, analytics, and virtualization.
BUENOS AIRES - 10 July, 2025 - Argentina is known as the meat capital of the world. Now its paving the way for cutting edge meat production employing AI and blockchain technology. Leading this effort is Hernán Santestevan, a thirty‑seven‑year‑old tech entrepreneur from Rosario, one of the principal architects of Latin America’s fast‑moving food‑technology renaissance.
Cintas delivered Q1 results that met Wall Street’s revenue expectations and exceeded consensus profit estimates, prompting a significant positive response from the market. Management attributed the quarter’s performance to broad-based growth across its core Uniform Rental, First Aid and Safety, and Fire Protection segments. CEO Todd Schneider highlighted the company’s focus on operational efficiency, particularly through technology investments like SAP and SmartTruck, which enabled higher gross margins and improved service delivery. Schneider emphasized that Cintas’s ability to leverage its scale and streamline processes allowed the company to maintain strong customer retention and stable purchasing behaviors, even amid a more uncertain macroeconomic environment.
BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- JA Worldwide and SAP are proud to announce a new global partnership that will equip tens of thousands of young people with the skills, confidence, and experience they need to thrive in the rapidly evolving world of work.
By integrating RISE with SAP, SAP S/4HANA, SAP Cloud ALM, Worksoft 14.5 delivers AI-powered test automation that helps businesses accelerate migrations, improve testing outcomes and reduce risk across the SAP ecosystem.
Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review Phase 2 MS trial results and discuss a Phase 3 study targeting cognitive improvement.
